Key result
Oncologic agents, including classical and immunological therapies, produce a variety of cardiovascular adverse effects such as cardiomyopathy, heart failure, and coronary artery disease.
Why the study?
What are the cardiovascular adverse effects of classical and large molecule immunological anti-cancer agents in patients with cancer?
What are the cardiovascular adverse effects of classical and large molecule immunological anti-cancer agents in patients with cancer?
Answers are grounded in this paper and cite their sources.
This review highlights the diverse cardiovascular toxicities of anti-cancer therapies, emphasizing the need for cardio-oncology collaboration to manage these adverse effects.
INTRODUCTION: Patients with cancer are subject to the cardiotoxic effects of cancer therapy and as more patients survive cancer due to improved treatment they are exposed to various forms of cardiovascular (CV) disease as they age, and vice-versa. Such an interplay of age with both malignancy and CV disease may contribute to increased morbidity and mortality. AREAS COVERED: This two-part review considers the effects of cancer drug treatment on the CV system. In Part I, the various types of CV and cardiometabolic toxicity of anti-cancer drugs and the possible mechanisms involved are discussed. Also, among the specific oncologic agents, the CV effects of the classical agents and of the large molecule immunological agents (monoclonal antibodies, including immune checkpoint inhibitors) are detailed. EXPERT OPINION: Oncologic agents produce a variety of CV adverse effects, including cardiomyopathy and heart failure, peri-myocarditis, coronary artery disease, peripheral vascular disease, hypertension (HTN), cardiac arrhythmias, valvular heart disease, and pulmonary HTN. Both the oncologist and the cardiologist need to be aware of such adverse effects and of the specific agents that produce them. They need to join forces to prevent, anticipate, recognize, and manage such complications.
No takes yet. Share an insight, caveat, or question.
Manolis et al. (2018) conducted a review in Cancer and cardiovascular disease. Anti-cancer drugs was evaluated on Cardiovascular and cardiometabolic toxicity. Oncologic agents, including classical and immunological therapies, produce a variety of cardiovascular adverse effects such as cardiomyopathy, heart failure, and coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: